A study on the relationship between RRM1 single nucleotide polymorphisms and clinical characteristics in lung cancer patients

Chinese Journal of Lung Cancer

Volumn 11, Issue 6, 2008, Pages 784-788

  Lin, Li ^a   Liu, Xiaoqing ^a   Song, Santai ^a   Wang, Shengqi ^b  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

Author keywords

Gemcitabine; Lung neoplasms; Ribonucleotide reductase subunit M1; Single nucleotide polymorphism

Indexed keywords

GEMCITABINE; GENOMIC DNA;

ALLELE; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENE; GENE FREQUENCY; GENE SEQUENCE; GENOTYPE; HUMAN; LEUKOCYTE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; REAL TIME POLYMERASE CHAIN REACTION; RIBONUCLEOTIDE REDUCTASE SUBUNIT M1 GENE; SEX; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 58549116700     PISSN: 10093419     EISSN: 19996187     Source Type: Journal    
DOI: 10.3779/j.issn.1009-3419.2008.06.17     Document Type: Article

References (9)

1. Danzinger S, Filipits M. Biomarkers the way towards individualized chemotherapy in non-small cell lung cancer (NSCLC). Wien Med Wochenschr, 2007, 157(21-22): 554-561.
2. Rosell R, Felip E, Paz-Ares L. How could pharmacogenomics help improve patient survival. Lung Cancer, 2007, 57(Suppl 2): 35-41.
3. Simon G, Sharma A, Li X, et al. Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer. J Clin Oncol, 2007, 25(19): 2741-2746.
4. Song PF, Li S, Meibohm B, et al. Detection of MDR1 single nucleotide polymorphisms C3435T and G2677T using real-time polymerase chain reaction: MDR1 single nucleotide polymorphism genotyping. Assay AAPS Pharm Sci, 2002, 4(4): 1-6.
5. Bepler G, Zhong Zh, Gautam A, et al. Ribonucleotide reductase M1 gene promoter activity polymorphisms, population frequencies and clinical relevance. Lung cancer, 2005, 47(2): 183-192.
6. Taron M, Alberola V, Sanchez JJ, et al. Transcription-coupled repair (TCR) XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/ cisplatin (cis) outcome in non-small-cell lung cancer (NSCLC). 2003 ASCO Annual Meeting (Abstr 2579).
7. Cardenal F, Ramir ez JL, Taron M, et al. XPD and RRM1 gene polymorphisms predict gemcitabine (gem)/cisplatin (cis)/docetaxel (doc) outcome in stage III non-small-cell lung cancer (NSCLC): A genetic analysis of the Spanish Lung Cancer Group phase II trial 9901. 2003 ASCO Annual Meeting (Abstr 2612).
8. Kim SO, Jeong JY, Kim MR, et al. Efficacy of gemcitabine in patients with non-small cell lung cancer according to promoter polymorphisms of the ribonucleotide reductase M1 gene. Clin Cancer Res, 2008, 14(10): 3083-3088.
9. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med, 2007, 356(8): 800-808.